Nath Bio-Genes (India) Ltd Q1 FY27 Results — Earnings Call Analysis
Published 17 Jun 2026 | Agricultural Food & other Products | Market Cap: ₹373 Cr
- Cotton volume is expected to grow around 20%, consistent with the 22% growth achieved in FY26. - Revenue growth for FY27 is expected between 15-20%, driven by strong volume growth in cotton (22%), paddy (25%), and maize (54%).
From Nath Bio-Genes (India) Ltd's Q4 FY26 earnings-call transcript · updated 17 Jun 2026.
Price
₹167
Market Cap
₹373 Cr
P/E Ratio
9.6
Revenue Rank
Margin Rank
How does Nath Bio-Genes (India) Ltd rank in Agricultural Food & other Products?
Compare Nath Bio-Genes (India) Ltd against every Agricultural Food & other Products company this quarter on revenue, margins and earnings-call signals.
Nath Bio-Genes (India) Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹52 Cr, net profit ₹0 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →Cotton volume is expected to grow around 20%, consistent with the 22% growth achieved in FY26.
- →Paddy volume growth is anticipated at 20-25%, reflecting strong performance.
- →Maize is a key growth driver, with significant volume surge of 54% in FY26 and expected to maintain strong growth.
- →Overall top-line (revenue) growth for FY27 is conservatively projected between 15-20%.
- →EBITDA margins and net profit margins are expected to maintain a slight upward trend.
- →The company is confident in scaling operations sustainably, backed by a stable production base, growing market presence, and robust product pipeline.
- →International business is nascent but growing; from INR 15 crores currently in Uzbekistan, long-term international revenue is targeted at 10-15% of total sales.
- →Inventory build-up is planned to meet anticipated demand, reinforcing growth outlook.
📈 Profitability & Margins
Rank 3- →Revenue growth for FY27 is expected between 15-20%, driven by strong volume growth in cotton (22%), paddy (25%), and maize (54%).
- →EBITDA margin is anticipated to maintain or show a slight upward trend, leading to improved net profit margins.
- →PAT performance is expected to remain healthy, with slight increase in marketing and finance costs considered manageable.
- →EPS has doubled over five years (INR 11.3 in FY22 to INR 23.42 in FY26), reflecting sustained value creation; growth momentum to continue.
- →Company maintains a conservative outlook, preferring to under-commit and over-perform.
- →Growth aided by expanded product portfolio, market penetration, especially in maize, and international expansion (Uzbekistan contributing INR 15 crores).
- →Sales and marketing spend will be commensurate with revenue growth, maintaining healthy margins.
- →Overall, Nath Bio-Genes is confident of sustained quality growth and improved profitability in FY27 and beyond.
🏗️ Capital Expenditure Plans
No- →Nath Bio-Genes follows a conservative CapEx policy focusing mainly on land bank and vehicles necessary for sales and production.
- →The company avoids heavy investments in processing plants and storage facilities, opting instead for rentals, as the need for such infrastructure is limited and seasonal (e.g., maize requires about 15-20 days of processing).
- →For FY27, there are no significant planned CapEx investments in processing capacity, cold storage, or new geographies.
- →The strategy favors minimal CapEx with an emphasis on operational efficiency and leveraging existing external infrastructures rather than owning them.
💰 Fundraising & Capital Structure
No information- →No specific mention of any current or planned fundraising through debt or equity in the call.
- →Finance costs increased due to deliberate working capital investment for inventory build-up, but this is managed from existing resources.
- →The company has substantial cash and bank balances (INR 707 million) and bank deposits (INR 70-80 crores), indicating no urgent need for external fundraising.
- →CapEx investments are minimal and focused only on land bank and vehicles, avoiding large capital expenditures.
- →The company prefers conservative commitments and aims for organic growth rather than leveraging through debt or equity issuance at this time.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Nath Bio-Genes (India) Ltd Q1 FY27 results?
- Cotton volume is expected to grow around 20%, consistent with the 22% growth achieved in FY26. - Revenue growth for FY27 is expected between 15-20%, driven by strong volume growth in cotton (22%), paddy (25%), and maize (54%).
What is Nath Bio-Genes (India) Ltd share price analysis?
Nath Bio-Genes (India) Ltd currently shows a below-average growth signal. The stock trades at a P/E of 9.6 with a market cap of ₹372. Investors should review the full earnings analysis for detailed insights.
Is Nath Bio-Genes (India) Ltd planning capital expenditure?
- Nath Bio-Genes follows a conservative CapEx policy focusing mainly on land bank and vehicles necessary for sales and production.
Keep Nath Bio-Genes (India) Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.